Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7883530 | 0.84 | DRD2 (0.79) | DRD2DRD3 | |
| SCHEMBL11205417 | 0.82 | DRD2 (1.00) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL11243427 | 0.81 | DRD2 (0.97) | DRD2DRD3 | |
| SCHEMBL7885003 | 0.80 | DRD2 (0.68) | DRD2DRD3 | |
| SCHEMBL3032548 | 0.79 | DRD2 (0.66) | DRD2DRD3 | |
| SCHEMBL10075561 | 0.79 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL7886406 | 0.79 | DRD2 (0.81) | DRD2DRD3 | |
| SCHEMBL3030252 | 0.78 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL30350412 | 0.78 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL10075562 | 0.78 | DRD2 (1.00) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD3 7/4885 |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | HTR3A, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.